Document is current
Any future updates will be listed below
-
Authors
Witte, Julian https://orcid.org/0000-0003-2075-323X
Touchot, Nicolas https://orcid.org/0009-0008-6131-8983
Surmann, Bastian https://orcid.org/0000-0003-1655-0907
Braegelmann, Kylie https://orcid.org/0000-0001-6578-8319
Flume, Mathias https://orcid.org/0000-0001-8512-9097
Beckhaus, Julia https://orcid.org/0000-0002-5877-5496
Friedrich, Carsten
Müller, Hermann L. https://orcid.org/0000-0003-4929-9966
-
Funding
Funding for this research was provided by:
Rhythm Pharmaceuticals (Rhythm Pharmaceuticals)
- License Information
-
More Information
Article History
Received: 6 June 2024
Accepted: 16 April 2025
First Online: 9 May 2025
Declarations
:
: As the study did not gather patient or individual individual-level data or involve any interventions, formal ethical approval was not sought, and informed consent was not applicable.
: J.W., K.B., B.S., H.L.M, J.B., and N.T. prepared the manuscript. All other co-authors reviewed and approved the manuscript. Medical writing/editing support was provided by Excerpta Medica, funded by Rhythm Pharmaceuticals.
: J.W. and M.B. own shares in Vandage GmbH. B.S. and K.B. are employed by Vandage. Vandage received funding from Rhythm pharmaceutical to perform the study related to this manuscript. Vandage received payments from Rhythm, Alexion, AstraZeneca, BMS, GSK, Janssen, Moderna, MSD, Pfizer, PTC Therapeutics, Sanofi Pasteur, Seqirus, Viatris and consulting fees and grants from AOK Rheinland/Hamburg, BARMER, DAK-Gesundheit, German G-BA, and Techniker Krankenkasse. H.L.M. has received reimbursement of participation fees for scientific meetings and continuing medical education events from the following companies: Ferring, Lilly, Pfizer, Sandoz/Hexal, Novo Nordisk, IPSEN, Rhythm, and Merck Serono; he has received reimbursement of travel expenses from IPSEN and lecture honoraria from Pfizer. N.T. is employed by Rhythm Pharmaceuticals. J.B. and C.F. have nothing to disclose.
